drugset
drugset / Trial / NCT03736564

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

NCT03736564 ↗

Phase 1/2 Completed 18 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.

Timeline

Start
2019-01-31
Primary completion
2023-10-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATATE Diagnostic / imaging agent — Intravenous

Indications

osteomalacia